Literature DB >> 12835672

Umbilical-cord blood transplantation for the treatment of cancer.

Juliet N Barker1, John E Wagner.   

Abstract

Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited by the lack of suitable bone-marrow donors, the risk of graft-versus-host disease (GVHD) and slow immune reconstitution. Umbilical-cord blood is an alternative source of haematopoietic stem cells that has recently been tested in both child and adult cancer patients. These studies have identified several advantages to umbilical-cord cell transplantation, including a lower incidence of GVHD. Umbilical-cord blood is therefore a promising alternative to bone-marrow-derived stem cells.

Entities:  

Mesh：

Year:  2003        PMID： 12835672     DOI： 10.1038/nrc1125

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  29 in total

Review 1.  Migration and fate of therapeutic stem cells in different brain disease models.

Authors:  B J Carney; K Shah
Journal:  Neuroscience       Date:  2011-09-14       Impact factor: 3.590

Review 2.  Who is fit for allogeneic transplantation?

Authors:  H Joachim Deeg; Brenda M Sandmaier
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

3.  Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Authors:  Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Tontanai Numbenjapon; Jennifer Bennitt; Daniel Kim; David Smith; George McNamara; Zaid Al-Kadhimi; Joseph Rosenthal; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 4.  Cryopreservation of hematopoietic stem cells.

Authors:  David Berz; Elise M McCormack; Eric S Winer; Gerald A Colvin; Peter J Quesenberry
Journal:  Am J Hematol       Date:  2007-06       Impact factor: 10.047

5.  4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.

Authors:  Syam Tammana; Xin Huang; Marianna Wong; Michael C Milone; Linan Ma; Bruce L Levine; Carl H June; John E Wagner; Bruce R Blazar; Xianzheng Zhou
Journal:  Hum Gene Ther       Date:  2010-01       Impact factor: 5.695

6.  Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional.

Authors:  Qin Tang; Bartosz Grzywacz; Hongbo Wang; Nandini Kataria; Qing Cao; John E Wagner; Bruce R Blazar; Jeffrey S Miller; Michael R Verneris
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

7.  Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

Authors:  Andreas K Nussler; Katrin Zeilinger; Lilianna Schyschka; Sabrina Ehnert; Jörg C Gerlach; Xueying Yan; Serene M L Lee; Maren Ilowski; Wolfgang E Thasler; Thomas S Weiss
Journal:  J Mater Sci Mater Med       Date:  2011-04-03       Impact factor: 3.896

8.  Maitake beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse.

Authors:  Hong Lin; Elisa De Stanchina; Xi Kathy Zhou; Yuhong She; Danthanh Hoang; Sandy Wy Cheung; Barrie Cassileth; Susanna Cunningham-Rundles
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-14

9.  Expansion of cord blood CD34 cells in presence of zVADfmk and zLLYfmk improved their in vitro functionality and in vivo engraftment in NOD/SCID mouse.

Authors:  Sangeetha V M; V M Sangeetha; Vaijayanti P Kale; Lalita S Limaye
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

Review 10.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.